

# Joseph F Merola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/724640/publications.pdf>

Version: 2024-02-01

212  
papers

5,622  
citations

109264

35  
h-index

106281

65  
g-index

218  
all docs

218  
docs citations

218  
times ranked

4946  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 377, 1537-1550.	13.9	434
2	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
3	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	1.5	264
4	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019, 15, 153-166.	3.5	208
5	Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019, 129, 1359-1371.	3.9	177
6	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10.	0.6	163
7	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	13.9	143
8	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	0.6	137
9	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	6.3	122
10	A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. <i>British Journal of Dermatology</i> , 2018, 179, 642-650.	1.4	119
11	Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis. <i>JAMA Dermatology</i> , 2016, 152, 944.	2.0	114
12	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2018, 154, 934.	2.0	112
13	Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. <i>Dermatologic Therapy</i> , 2018, 31, e12589.	0.8	95
14	Distinguishing rheumatoid arthritis from psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000656.	1.8	90
15	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2a”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	0.6	88
16	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 844-852.	1.4	87
17	Comorbidities associated with psoriatic arthritis: Review and update. <i>Clinical Immunology</i> , 2020, 214, 108397.	1.4	83
18	Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 345-352.	0.6	75

#	ARTICLE	IF	CITATIONS
19	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
20	Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 79-87.e1.	0.6	70
21	Switching biologics in the treatment of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 29-37.	1.6	69
22	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	0.6	69
23	Psoriasis, psoriatic arthritis and risk of gout in US men and women. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1495-1500.	0.5	67
24	TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 70-80.	0.3	67
25	Epidemiology and Treatment of Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2016, 152, 97.	2.0	60
26	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (<sc>UNCOVER</sc>â€1, <sc>UNCOVER</sc>â€2 and <sc>UNCOVER</sc>â€3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1686-1692.	1.3	60
27	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 102-110.	0.6	52
28	Psoriatic arthritis for dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, 31, 662-679.	1.1	52
29	Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. <i>Lupus</i> , 2014, 23, 778-784.	0.8	50
30	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 261-267.	0.6	48
31	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1367-1374.	0.6	48
32	The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 345-348.	0.6	44
33	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43
34	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	2.0	41
35	Axial psoriatic arthritis: An update for dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 92-101.	0.6	41
36	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017, 7, e014733.	0.8	37

#	ARTICLE	IF	CITATIONS
37	Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 19-24.	0.6	36
38	Treatment of coexistent psoriasis and lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 253-260.	0.6	36
39	Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 797-806.	1.3	36
40	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017, 44, 693-694.	1.0	33
41	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018, 178, 715-721.	1.4	33
42	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	1.4	30
43	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1215-1219.	0.5	29
44	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 80-86.	0.5	29
45	Diagnosing and treating psoriatic arthritis: an update. <i>British Journal of Dermatology</i> , 2014, 170, 772-786.	1.4	28
46	Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature. <i>Dermatology</i> , 2016, 232, 97-101.	0.9	27
47	Histopathology of the Inner Ear in a Case With Recent Onset of Cogan's Syndrome. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2016, 125, 20-24.	0.6	27
48	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1150-1159.	0.6	27
49	Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. <i>Clinical Rheumatology</i> , 2018, 37, 2751-2761.	1.0	26
50	Measuring fatigue: a meta-review. <i>International Journal of Dermatology</i> , 2021, 60, 1053-1069.	0.5	26
51	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020, 182, 410-417.	1.4	25
52	Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study. <i>Journal of Rheumatology</i> , 2020, 47, 548-552.	1.0	24
53	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2212-2220.	2.3	24
54	Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 701-702.	0.6	23

#	ARTICLE	IF	CITATIONS
55	Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. <i>Journal of Dermatological Treatment</i> , 2019, 30, 141-149.	1.1	23
56	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	3.5	23
57	Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 71-78.	0.6	23
58	Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. <i>Current Atherosclerosis Reports</i> , 2021, 23, 67.	2.0	23
59	Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. <i>British Journal of Dermatology</i> , 2018, 178, 1412-1415.	1.4	22
60	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <i>Current Rheumatology Reports</i> , 2018, 20, 76.	2.1	22
61	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	2.0	22
62	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021, 157, 805.	2.0	21
63	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021, 185, 1124-1134.	1.4	21
64	Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 147-162.	3.3	20
65	Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA-BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1178-1180.	0.6	20
66	Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 321-329.	0.6	20
67	Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey. <i>Rheumatology and Therapy</i> , 2019, 6, 33-45.	1.1	20
68	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	0.6	20
69	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 748-757.	0.6	20
70	Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing. <i>Journal of Rheumatology</i> , 2015, 42, 847-852.	1.0	19
71	Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. <i>Journal of Rheumatology</i> , 2019, 46, 160-165.	1.0	19
72	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 692-703.	1.4	19

#	ARTICLE	IF	CITATIONS
73	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	1.0	18
74	Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678.	1.0	18
75	Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis. <i>JAMA Dermatology</i> , 2017, 153, 944.	2.0	18
76	Evaluation of sPGA – BSA as an Outcome Measure and Treatment Target for Clinical Practice. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1955-1961.	0.3	18
77	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus – An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 270-276.	0.3	18
78	Coronary microvascular dysfunction in patients with psoriasis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 37-42.	1.4	18
79	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2020, 156, 901.	2.0	18
80	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020, 10, 351-364.	1.4	18
81	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020, 7, 617-637.	1.1	17
82	Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 86-93.	0.6	16
83	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020, 156, 342.	2.0	16
84	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: 3-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1959-1970.	2.9	16
85	Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. <i>Clinics in Dermatology</i> , 2018, 36, 551-560.	0.8	15
86	Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study. <i>Rheumatology and Therapy</i> , 2018, 5, 423-436.	1.1	15
87	De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 864-869.	0.6	15
88	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 431-431.	0.7	15
89	Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 423-425.	0.6	15
90	Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1257-1262.	1.3	14

#	ARTICLE	IF	CITATIONS
91	Psoriatic arthritis: It's as easy as "PSA". Journal of the American Academy of Dermatology, 2015, 72, 905-906.	0.6	13
92	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2809-2820.	1.3	13
93	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology, 2021, 60, 1137-1147.	0.9	13
94	Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus?. Journal of Drugs in Dermatology, 2011, 10, 1413-20.	0.4	13
95	The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): A Novel Index to Measure All Non-plaque Psoriasis Subsets. Journal of Rheumatology, 2014, 41, 1230-1232.	1.0	12
96	Classifying discoid lupus erythematosus: background, gaps, and difficulties. International Journal of Women's Dermatology, 2017, 3, S62-S66.	1.1	12
97	The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update. Journal of Drugs in Dermatology, 2017, 16, 119-124.	0.4	12
98	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. Journal of Rheumatology, 2022, 49, 885-893.	1.0	12
99	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. JAAD Case Reports, 2021, 17, 126-129.	0.4	11
100	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open, 2022, 8, e002195.	1.8	11
101	Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. Journal of Medical Economics, 2018, 21, 745-754.	1.0	10
102	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Archives of Dermatological Research, 2018, 310, 701-710.	1.1	10
103	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. Dermatology, 2018, 234, 157-165.	0.9	10
104	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Current Rheumatology Reports, 2020, 22, 78.	2.1	10
105	&lt;p>&gt;Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study&lt;/p>&lt;p>&gt;. Patient Preference and Adherence, 2020, Volume 14, 949-961.	0.8	10
106	Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire. Journal of Drugs in Dermatology, 2016, 15, 1011-6.	0.4	10
107	Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatology and Therapy, 2022, 9, 935-955.	1.1	10
108	Mosaic focal dermal hypoplasia caused by a novel somatic mutation in <i><sc>PORCN</sc></i> detected in affected skin. British Journal of Dermatology, 2015, 173, 568-570.	1.4	9

#	ARTICLE	IF	CITATIONS
109	Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 961-964.	1.0	9
110	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	1.0	9
111	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1337-1345.	0.6	9
112	Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 399-400.	0.6	9
113	Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. <i>Lupus Science and Medicine</i> , 2021, 8, e000529.	1.1	9
114	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960.	1.0	8
115	Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). <i>BMC Dermatology</i> , 2017, 17, 11.	2.1	8
116	Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA $\times$ BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. <i>Dermatology</i> , 2019, 235, 348-354.	0.9	8
117	<sc>SEAM</sc>: Seems Like Methotrexate Works in Psoriatic Arthritis?. <i>Arthritis and Rheumatology</i> , 2019, 71, 1027-1029.	2.9	8
118	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	1.0	8
119	Does psoriasis treatment affect PsA development?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 708-709.	3.5	8
120	Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPSAKE 1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	8
121	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Women's Dermatology</i> , 2016, 2, 8-12.	1.1	7
122	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828.	0.6	7
123	Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 577-578.	0.6	7
124	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1670-1675.	1.1	7
125	Tofacitinib for refractory chilblain lupus erythematosus. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	7
126	Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. <i>Journal of Rheumatology</i> , 2022, 49, 894-902.	1.0	7



#	ARTICLE	IF	CITATIONS
127	Plasma levels of tumour necrosis factor $\alpha$ and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 379-380.	1.4	6
128	OPO108...DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
129	Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 109-117.	3.3	6
130	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 323-338.	3.3	6
131	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021, 237, 151-157.	0.9	6
132	Mycophenolate Mofetil for Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2020, 156, 595.	2.0	6
133	Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 495-497.	0.6	6
134	RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin. <i>Lupus Science and Medicine</i> , 2021, 8, e000428.	1.1	6
135	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201671.	1.0	6
136	Hidradenitis suppurativa and sleep disorders: a population-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e520-e522.	1.3	6
137	Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2021, 157, 880-882.	2.0	6
138	A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1907-1915.	1.1	6
139	A case of paradoxical fibrosis and development of morphea in a patient on dupilumab. <i>JAAD Case Reports</i> , 2021, 17, 7-8.	0.4	6
140	Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists. <i>Clinical Rheumatology</i> , 2022, 41, 1271-1283.	1.0	6
141	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022, 12, 787-800.	1.4	6
142	Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. <i>Scandinavian Journal of Rheumatology</i> , 2022, , 1-9.	0.6	6
143	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. <i>International Journal of Women's Dermatology</i> , 2016, 2, 44-45.	1.1	5
144	Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1325-1329.	0.3	5

#	ARTICLE	IF	CITATIONS
145	SAT0222â€¦BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. , 2017, , .		5
146	Inflammatory arthritis and crystal arthropathy: Current concepts of skin and systemic manifestations. Clinics in Dermatology, 2018, 36, 533-550.	0.8	5
147	Older adults on systemic treatment for psoriasis and risk of infection: a propensity scoreâ€matched populationâ€based study. British Journal of Dermatology, 2020, 183, 564-566.	1.4	5
148	The National Psoriasis Foundation psoriasis treatment targets in realâ€world patients: prevalence and association with patientâ€reported outcomes in the Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2051-2058.	1.3	5
149	Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis. Dermatology and Therapy, 2021, 11, 1199-1216.	1.4	5
150	International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. Journal of Drugs in Dermatology, 2017, 16, 770-777.	0.4	5
151	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. Journal of the American Academy of Dermatology, 2020, 82, 54-61.	0.6	4
152	Severe recalcitrant otic lichen planus treated with mycophenolate mofetil. JAAD Case Reports, 2021, 8, 1-3.	0.4	4
153	Seroconversion of severe acute respiratory syndrome coronavirus 2â€infected patients on immunosuppression: A retrospective analysis. Journal of the American Academy of Dermatology, 2021, 84, 1409-1412.	0.6	4
154	Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist. Journal of the American Academy of Dermatology, 2022, 87, 1075-1080.	0.6	4
155	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BEâ€VIVID and BEâ€READY Phaseâ€3 Trials. Dermatology and Therapy, 2021, 11, 1551-1569.	1.4	4
156	Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey. British Journal of Dermatology, 2021, 185, 1264-1265.	1.4	4
157	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	0.9	4
158	Targeted therapies for psoriatic arthritis: an update for the dermatologist. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 173-181.	1.6	4
159	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. Rheumatology Advances in Practice, 2021, 5, rkab076.	0.3	4
160	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatology and Therapy, 2022, 12, 911.	1.4	4
161	Novel posterior auricular cutaneous reaction after antiâ€TNF-Î± infusion in young women with Crohn's disease. JAAD Case Reports, 2017, 3, 512-514.	0.4	3
162	OPO216â€...Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. , 2017, , .		3

#	ARTICLE	IF	CITATIONS
163	SAT0390â€¦Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported psoriatic arthritis in the randomized, double-blind, head-to-head comparison study Eclipse over 1 year. , 2019, , .		3
164	Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021, 11, 253-263.	1.4	3
165	Pustular Psoriasis and Associated Musculoskeletal Disorders. <i>Journal of Rheumatology</i> , 2021, , jrheum.201673.	1.0	3
166	Hepatitis B and C among patients with hidradenitis suppurativa: a populationâ€based study. <i>International Journal of Dermatology</i> , 2022, 61, 84-88.	0.5	3
167	Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients. <i>JAAD International</i> , 2021, 3, 111-114.	1.1	3
168	Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4081.	1.0	3
169	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	1.0	3
170	Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitasâ€™ Psoriasis Registry. <i>Dermatology and Therapy</i> , 2022, 12, 97-119.	1.4	3
171	Psoriatic arthritis screening tools: study design and methodological challenges. <i>British Journal of Dermatology</i> , 2014, 170, 994-995.	1.4	2
172	Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 695-696.	1.0	2
173	Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 691-692.	1.0	2
174	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 267-283.	1.3	2
175	Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 249-252.	0.6	2
176	Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 40-43.	1.0	2
177	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32.	1.0	2
178	FRI0580â€¦Comorbidity Burden and Medication Use between Psoriatic Arthritis Patients with Moderate-To-Severe Psoriasis vs. Those with Minimal Skin Psoriasis in The US. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 651.3-652.	0.5	1
179	83â€¦Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus. , 2017, , .		1
180	405â€¦Temporal relationship of cutaneous lupus erythematosus and systemic lupus erythematosus: a large, retrospective cohort study. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
181	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	0.9	1
182	AB0742â€¦ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
183	AB0738â€¦DUAL NEUTRALISATION OF INTERLEUKIN (IL)â€“17A AND ILâ€“17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. , 2019, , .		1
184	FRI0458â€¦OBJECTIVE MEASURES OF PSORIASIS SEVERITY AND THE RISK FOR PSA: RESULTS FROM THE INCIDENT HEALTH OUTCOMES AND PSORIASIS EVENTS PROSPECTIVE COHORT STUDY. , 2019, , .		1
185	An Approach to Retiform Purpura for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2019, 8, 245-257.	1.1	1
186	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020, 20, S80-S83.	0.8	1
187	Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. <i>RMD Open</i> , 2021, 7, e001484.	1.8	1
188	Lack of association between tumor necrosis factor-Î± inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	1
189	Step Therapy Re-Imagined. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 88-89.	0.3	1
190	The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 517-519.	0.6	1
191	Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1106-1117.	0.5	1
192	Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 753-760.	1.4	1
193	Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. <i>Journal of Dermatological Treatment</i> , 2022, , 1-28.	1.1	1
194	Ixekizumab provides persistent improvements in healthâ€related quality of life and the sexual impact associated with moderateâ€toâ€severe genital psoriasis in adult patients during a 52â€week, randomised, placeboâ€controlled, phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
195	Topical tofacitinib for the management of lymphocyticâ€variant hypereosinophilic syndrome with cutaneous involvement. <i>Dermatologic Therapy</i> , 2022, 35, e15518.	0.8	1
196	SAT0437â€¦Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response. , 2017, , .		0
197	SAT0461â€¦Characterisation of different low disease activity measurements in patients with psoriatic arthritis. , 2017, , .		0
198	Polyarthralgias and Papulonodules in a 56â€Yearâ€Old Woman. <i>Arthritis Care and Research</i> , 2018, 70, 925-930.	1.5	0

#	ARTICLE	IF	CITATIONS
199	THU0313â€¦Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors. , 2018, , .		0
200	AB0783â€¦RELATIVE IMPACT OF JOINT AND SKIN SYMPTOMS ON QUALITY OF LIFE AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS (PSA) PATIENTS. , 2019, , .		0
201	FR10452â€¦TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES. , 2019, , .		0
202	P279â€¦Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year. Rheumatology, 2020, 59, .	0.9	0
203	Indoor tanning use is associated with psoriasis in the Nursesâ€™ Health Study II. British Journal of Dermatology, 2020, 183, 384-386.	1.4	0
204	Pseudovasculitis: an etiology not to miss. Clinical Rheumatology, 2021, 40, 2505-2506.	1.0	0
205	P189â€¦Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study. Rheumatology, 2021, 60, .	0.9	0
206	Non-Medical Switching Impact on Patients and Providers â€” Psoriatic Disease Community Taking a Stand. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 126-127.	0.3	0
207	AB0929â€¦Burden of skin and joint symptoms of psoriatic disease: results of a multi-national patient survey. , 2018, , .		0
208	Efficacy of Dupilumab in Atopic Dermatitis: The Patientâ€™s Perspective. Dermatology and Therapy, 2021, 11, 2123-2131.	1.4	0
209	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4.	0.3	0
210	A novel variant in the GNAS complex locus causes Albright hereditary osteodystrophy with pseudopseudohypoparathyroidism. JAAD Case Reports, 2022, 21, 103-105.	0.4	0
211	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. Journal of Rheumatology, 2022, , jrheum.211328.	1.0	0
212	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , .	1.0	0